Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.

Jenny SprootenAnn VankerckhovenIsaure VanmeerbeekDaniel M BorrasYani BerckmansRoxanne WoutersRaquel S LaureanoThais BaertLouis BoonChiara LandolfoAntonia Carla TestaDaniela FischerovaCaroline Van HolsbekeTom BourneValentina ChiappaWouter FroymanDominique ScholsPatrizia AgostinisDirk TimmermanSabine TejparIgnace VergoteAn Coosemans Abhishek Dinkarnath Garg

Published in: Journal for immunotherapy of cancer (2022)

We established sFIS assay as a novel biomarker resource for serum screening in patients with OV to evaluate peripheral immunodynamics, patient survival trends and malignancy risk, and to design preclinical chemo-immunotherapy strategies.

Keyphrases

dendritic cells
photodynamic therapy
case report
immune response
bone marrow
acute myeloid leukemia
radiation therapy
mesenchymal stem cells
combination therapy